Ubiquitination regulates several biological processes. Here, we search for ubiquitin-related 32 genes implicated in protein membrane trafficking performing a High-Content siRNA 33 Screening including 1,187 genes of the human "ubiquitinome" using Amyloid Precursor 34 Protein (APP) as a reporter. We identified the deubiquitinating enzyme PSMD14, a subunit 35 of the 19S regulatory particle of the proteasome, specific for K63-Ub chains in cells, as a 36
Introduction 46
Several post-translational modifications (PTMs) contribute to membrane transport 1,2 . 47 Among these, ubiquitination acts as a relevant player in protein membrane trafficking 3-5 48 participating as an important protein localization signal 3,6-8 . However, to date most studies 49 have focused on its role in endocytosis, particularly in the inclusion of cargoes in 50 intraluminal vesicles (ILVs) of multivesicular bodies (MVBs) 9-11 such as cell-surface 51 receptors 12 . Ubiquitination is a regulated post-translational modification that conjugates 52 ubiquitin (Ub) to lysine (K) residues and is involved in many cellular pathways including 53 the degradation of target proteins through the proteasomes and autophagy 13, 14 . Ubiquitin 54 modification is a cascade of reactions catalyzed by three classes of enzymes (E1, E2 and 55 E3). An ATP dependent E1 activating enzymes first forms a covalent intermediate with 56
ubiquitin, followed by the transfer of Ub to E2 conjugating enzymes and finally the 57 covalent attachment of Ub to a K residue in the target protein by E3 Ub ligases 15 . 58
Ubiquitination is a reversible reaction, with specific deubiquitinating enzymes (DUBs) that 59 catalyze the removal of Ub-moieties for their recycling. DUBs serve to counterbalance 60 ubiquitination reactions within the cell, thus dynamically contributing to the regulation of 61 various cellular processes, such as endosomal sorting 11, [16] [17] [18] . 62
Ub increases proteome complexity, providing an additional surface for protein-protein 63 interactions and functional regulation 19, 20 . Ub-modified proteins and Ub chains are 64 recognized by several Ub receptors including a family of specialized proteins carrying Ub 65 binding domains (UBDs). To date, over 20 UBD families have been identified and 66 characterized in mammals participating in recognition of Ub monomers or Ub chains on 67 specific substrates 4,14,21 . Together, the Ub network offers a variety of choices to modulate 68 cellular processes including protein membrane trafficking. However, the contribution of the 69 ubiquitinome regarding their impact in intracellular membrane trafficking is not yet fully 70 understood. 71
To investigate the contribution of most of the members of the ubiquitinome in protein 72 membrane trafficking, we performed High-Content siRNA Screening (HCS) including 73 1,187 genes of the human "ubiquitinome". For this screening we used a stable cell line 74 expressing Amyloid Precursor Protein (APP) fused to EGFP. APP was the protein selected 75 as target because it traffics dynamically through the secretory and endocytic pathways 76 containing specific sorting signal motifs [22] [23] [24] and specific lysine residues targets of 77 ubiquitination [25] [26] [27] [28] . We thus identified the deubiquitinating (DUB) enzyme PSMD14, a 78 subunit of the 19S regulatory particle (RP) of the proteasome, as a crucial player of to-Endoplasmic reticulum (ER) retrograde transport. The DUB enzyme PSMD14 has been 80 shown to be specific for K63-Ub chains in cells 29 . Here, we found that the inhibition of its 81 activity blocks Golgi-to-ER retrograde transport causing the swelling of the Golgi 82 apparatus. Also, we found that PSMD14 inhibition acts as a potent blocker of 83 macroautophagy as a result of its negative impact in Golgi-to-ER retrograde transport. 84
Inhibition of the proteolytic core of the 20S proteasome by MG132 did not recapitulate 85 these effects, indicating that the 19S RP plays a role on macroautophagy by controlling 86 membrane trafficking at the early secretory pathway. 87
Results 88
High-Content siRNA Screening revealed PSMD14 deubiquitinating enzyme as a novel 89 regulator of protein trafficking. 90
To investigate the contribution of the ubiquitinome in protein membrane trafficking, we 91 performed an automated HCS using a human small interfering RNA (siRNA) 92 "ubiquitinome" library, consisting of 1,187 siRNA duplex pools targeting all known and 93 predicted Ub-genes. This library, used previously in mammalian screening assays 30,31 94 includes E1 activating enzymes (0.8%), E2 conjugating enzymes (4.7%), E3 Ub ligases 95 (61.2%), UBD-containing proteins (12.8%), DUBs (8.8%), SUMO-specific proteases 96 (SENPs) (0.2%) and others (11.4%) ( Fig. 1A ). We used this library to identify novel 97 regulators of protein membrane trafficking using an H4 neuroglioma cell line stably 98 expressing APP-EGFP, a cell line previously characterized and used in siRNAs knockdown 99 experiments 24, 32, 33 . We standardized the basal (background) and maximum fluorescence 100 intensity by analyzing total fluorescence of silenced and non-silenced APP-EGFP, 101 respectively. A reduction in total fluorescence intensity from 100% to 6% was observed 102 with the EGFP siRNA, compared to the Non-Target (NT) siRNA with a Z factor of 0.69 103 ( Fig. 1B) . Representative images of basal and maximum levels of total fluorescence 104 intensity in reporter cells are shown in Fig. 1C . Cells were further assessed with a primary 105 siRNA screening consisting of a pool of four-different siRNA duplexes for each of the 106 1,187 genes selected, each siRNA targeting a distinct region to minimize their off-targets 107 effects 34 . Fig. 1D shows a summary of the results with all siRNA pools tested and 108 normalized in respect to the expression of the NT siRNA. Among the 1,187 tested genes, 109 we found that the highest total fluorescence increase (4.15-fold increase) corresponded to 110 protein PSMD14 (POH1, also known as Rpn11/MPR1/SS13/CepP1) ( Fig. 1D ), a subunit of 111 the 19S regulatory particle (RP) of the proteasome, which has DUB activity 35, 36 . 112
Representative images of reporter cells knock-down (KD) of PSMD14 in comparison to 113 cells transfected with NT siRNA are shown in Fig. 1E . Further, we validated these results 114 analyzing the effect of PSMD14 KD on the levels of full-length endogenous APP in 1 and 2, respectively). Quantification analysis showed a 3.13-fold increase of full-length 119 endogenous APP levels in PSMD14 KD cells, compared to Mock cells ( Fig. 2B ). Besides, 120
we found that silencing of PSMD14 caused a strong increase in high molecular weight Ub 121 conjugates, consistent with the role of PSMD14 as a proteasomal subunit with DUB 122 activity ( Fig. 2A , second panel, lanes 3-6 compared to lanes 1 and 2). Confirmation of the 123 efficient KD of PSMD14 with all four siRNAs tested was demonstrated by western blot 124 ( Fig. 2A , third panel, lanes 3-6 compared to lanes 1 and 2), observing a 5.22-fold decrease 125 on PSMD14 levels (Fig. 2C ). Moreover, efficient KD of PSMD14 was also determined by 126 quantitative reverse transcription PCR (RT-qPCR) ( Fig. 2D ). Finally, to evaluate whether 127 the increase of APP protein levels in PSMD14 KD cells could be the result of an up-128 regulation of APP transcription, we evaluated APP mRNA levels by RT-qPCR, observing 129 no significant changes ( Fig. 2E ). Altogether, these findings indicate that the silencing of 130 PSDM14 caused a robust increase of APP protein levels, a finding that could suggests 131 impairment in its turnover due to trafficking alterations. 132
Acute inhibition of the deubiquitinating enzyme PSMD14 of the 19S RP accumulates 133

APP in a swollen Golgi apparatus. 134
To determine whether PSMD14 is involved in the control of endogenous APP levels, we 135 investigated the effect of incubating cells with Capzimin (CZM), a potent and specific 136 inhibitor of the DUB activity of PSMD14 37 , a subunit of the 19S RP of the proteasome 137 ( Fig. 3A ). We observed that CZM led to a significant increment in full-length endogenous 138 APP levels in a dose-dependent manner, compared to untreated cells ( Fig. 3B and 3C ). 139
Interestingly, compared to untreated cells, and in contrast to CZM, treatment with a 140 standard concentration of 10 µM MG132, a reversible inhibitor of the b1, b2 and b5 141 subunits of the 20S catalytic core of the proteasome 38,39 ( Fig. 3A) , caused a significant 142 decrease in full-length endogenous APP levels ( Fig. 3B and 3C ). To confirm the inhibition 143 of PSMD14 by CZM, we tested the effect of this inhibitor on the levels of high molecular 144
weight Ub conjugates, comparing it with MG132. In agreement with the effect of PSMD14 145 KD, we observed that CZM caused a robust increase in high molecular weight Ub 146 conjugates in a dose-dependent manner, finding a maximum effect with 10 µM CZM ( Fig.  147 3D). However, we noticed that 10 µM MG132 caused a more powerful increase in Ub 148 conjugates ( Fig. 3D ). To confirm the accumulation of Ub conjugates by these treatments, 149 
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we studied the presence of Ub-inclusion bodies by immunofluorescence analysis. We found 150 that, compared to untreated cells ( To unveil this possibility, we performed an immunofluorescence analysis of endogenous 157 APP in parental H4 cells. We observed that the treatment with 10 µM CZM resulted in a 158 perinuclear redistribution of APP, which is highly indicative of Golgi apparatus localization 159 ( Fig. 4D , compared to 4A). Moreover, similar to the PSMD14 KD, we observed that the 160 CZM treatment caused a significant 2.50-fold increase in APP total fluorescence intensity 161 compared to untreated cells ( Fig. 4G ). We also observed a significant 1.92-fold increase in 162 the amount of APP in the area positive to the Golgi matrix protein GM130 (GM130), 163 compared to the total area ( Fig. 4F , compared to 4C and Fig. 4H ). Moreover, we observed 164 that the treatment with CZM caused a significant 1.30-fold increase in the total cell area 165 ( Fig. 4I ). In addition, we found that CZM caused the swelling of the Golgi apparatus ( Fig.  166 4E compared to 4B), a phenotype that is shown in a zoom in Fig. 4J . To confirm this 167 phenotype, we performed measurements of GM130 images from confocal 3D 168 reconstructions from the Z-stacks of cells treated with CZM ( Fig. 4K ). We observed a 1.53-169 fold increase in the Golgi apparatus volume in CZM treated cells, compared to control cells 170 ( Fig. 4L ). Similar results were observed in quantitative 2D image analysis, observing a 171 significant 2.53-fold increase in the Golgi apparatus area upon CZM treatment (Suppl. Fig.  172 1). Altogether, our results show that acute inhibition of PSMD14 by CZM accumulates 173 APP in a swollen Golgi apparatus. These findings strongly suggest that CZM impairs the 174 Golgi apparatus due to perturbations of the trafficking through this organelle. 175
Acute inhibition of the deubiquitinating enzyme PSMD14 perturbs Golgi-to-ER 176 retrograde transport 177
The Golgi apparatus is a highly dynamic organelle that requires fine regulation of 178 trafficking pathways in order to maintain its size, shape and composition. In particular, it 179 has been shown that Golgi-to-ER retrograde transport plays a crucial role in the 180 the Golgi-to-ER retrograde transport, we first validated our findings in HeLa cells. We 184 measured Golgi apparatus volume in 3D reconstructions from the Z-stacks of untreated 185
Figure 4
HeLa cells or treated with CZM and MG132 by using Giantin as Golgi apparatus reporter. 186
Similar to our findings in H4 cells, we found that the inhibition of PSMD14 DUB activity 187 by CZM causes a 2.14-fold increase in Golgi apparatus volume ( Fig. 5A , middle panel 188 compared to the left panel and 5B). Interestingly, in contrast to CZM, we observed that 189 MG132 caused no effect on Golgi apparatus volume ( Fig. 5A , right panel compared to the 190 left panel and 5B), strongly suggesting that Golgi homeostasis is regulated by the PSMD14 191 DUB activity. Then, we investigated whether this phenotype was the result of Golgi-to-ER 192 retrograde transport inhibition. We assessed the distribution of stably overexpressed KDEL 193 (Lys-Asp-Glu-Leu) Receptor 1 (KDELR1) fused to GFP (KDELR1-GFP) in HeLa cells. 194
As it was previously reported 44,46 , overexpressed KDELR1-GFP is mostly distributed to 195 the ER due to its efficient transport from the Golgi apparatus to the ER ( As before, we 203 tested the effect of MG132, observing no effect on the distribution of KDELR1-GFP ( Fig  204   5C , right panel compared to left panel, and 5D), which strongly supports that MG132 has 205 no effect on Golgi-to-ER retrograde transport. Next, to confirm blockage of Golgi-to-ER 206 retrograde transport by the acute inhibition of the PSMD14, we tracked the redistribution of 207 the transiently overexpressed thermo-sensitive KDELR1-VSVG-YFP chimera (vesicular 208 stomatitis virus G protein fused to KDEL receptor 1 and YFP) in HeLa cells upon treatment 209 with CZM by live cell imaging at different temperatures. Briefly, at a permissive 210 temperature of 32°C, KDELR1-VSVG-YFP cycles between the Golgi apparatus and the 211 ER, showing distribution mainly at the Golgi apparatus. Upon shifting to a restrictive 212 temperature of 40°C, KDELR1-VSVG-YFP is progressively accumulated at the ER due to 213 its specific retention in this compartment at this temperature. In addition, because the 214 Golgi-to-ER retrograde transport is not affected at 40ºC, the rapid decay of the fluorescence 215 of KDELR1-VSVG-YFP fluorescence at the Golgi apparatus, a measurement that is used to 216 evaluate inhibition of Golgi-to-ER retrograde transport pathway 47 . We found that in 217 control cells nearly 50% of the fluorescence of KDELR1-VSVG-YFP decayed after 15 min 218 of shifting the temperature to 40°C (Fig. 5E , upper panels and 5F), indicating that 219 retrograde transport is working normally 47 . In contrast, when cells were treated with CZM, 220 the decay of the fluorescence of KDELR1-VSVG-YFP was not apparent, confirming that 221 acute inhibition of the PSMD14 blocked Golgi-to-ER retrograde transport ( Fig. 5E , lower 222 panels and 5F). In contrast, MG132 treated cells showed similar results as controls (data not 223 shown), confirming that the 20S proteasome has no effect on retrograde transport. 224
Importantly, we found that CZM is able to block retrograde transport for short times having 225 no effect on the catalytic activity of the 20S proteasome (Suppl. Fig. 3 ). In contrast, a rapid 226 and robust inhibition on the catalytic activity of the 20S proteasome is observed with 227 MG132 (Suppl. Fig. 3 ). These findings strongly indicate that acute inhibition of PSMD14 228 DUB activity by CZM acts as a powerful blocker of Golgi-to-ER retrograde transport, 229 explaining the swelling of the Golgi apparatus and the accumulation of protein cargoes 230 such as APP at this location. 231
Inhibition of Golgi-to-ER retrograde transport by CZM has a negative impact on 232
macroautophagy. 233
Several lines of evidence have shown that Golgi-to-ER retrograde transport plays a relevant 234 role in autophagosome biogenesis at the level of the ER 48-51 . In addition, it has been shown 235 that PSMD14 participates in the activation of the aggresome clearance by cleaving K63 Ub 236 chains of aggregate proteins 52,53 . Thus, we investigated the effect of acute inhibition of 237 PSMD14 DUB activity on the number of autophagosomes by testing the classical marker 238 microtubule-associated protein 1 light chain 3B (LC3B) 54 . Therefore, parental H4 cells were 239 treated under nutrient starvation with Earle's balanced salt solution (EBSS), an established 240 culture medium used for activation of autophagosomal formation 55 . As expected, we found 241 that starvation strongly increased the number of autophagosomes ( Fig. 6B ), compared to 242 
90 min
cells treated under normal nutrient conditions ( Fig. 6A ). In contrast, we observed that 243 treatment with CZM abolished the appearance of autophagosomes upon EBSS treatment 244 ( Fig. 6C compared to 6B). We also tested the effect of CZM in cells under normal nutrients 245 conditions, but in the absence or presence of Torin-1, a potent and selective inhibitor of 246 mammalian target of rapamycin complexes (mTORC1/2), a trigger of autophagosomal 247 formation 56 . Similar to the results with EBSS, we observed that CZM prevented the 248 appearance of autophagosomes promoted by Torin-1 ( Fig. 6F compared to 6E) . In 249 agreement with these findings, we observed that CZM alone did not increase the number of 250 autophagosomes ( Fig. 6D compared to 6A) , in contrast to the effect of MG132 (Suppl. Fig.  251 4). To confirm these results, we quantified the number of LC3-positive structures under all 252 conditions tested, observing a significant decrease in the number of autophagosomes when 253 cells, treated with EBSS solution or Torin-1, where also treated with CZM ( Fig. 6G) . In 254 addition, we validated these results biochemically performing western blot analysis of 255 endogenous LC3B (Fig. 6H ). We found that the levels of LC3B-II were strongly increased 256 with EBSS or Torin-1 treatment (Fig. 6H, lanes 2 and 4) . In contrast, when cells were 257 treated with EBSS or Torin-1 in the presence of CZM, LC3B-II levels did not change (Fig.  258 6H, lanes 3 and 5) compared to control cells (Fig. 6H, lane 1) , results that were quantified 259 and depicted in Fig. 6J . Interestingly, this biochemical analysis also showed that CZM 260 increased LC3B-I levels under all conditions tested (Fig. 6H , lanes 3, 5 and 6, and Fig. 6I ) 261 compared to control cells (Fig. 6H , lane 1), suggesting that the reduction of the 262 autophagosomal structures caused by CZM was not due to a reduction in LC3B total levels. 263
Altogether, these results confirm that acute inhibition of PSMD14 DUB activity acts as a 264 potent blocker of autophagosome biogenesis induced by EBSS or Torin-1. In addition, 265 these findings suggest that blockage of autophagosomal biogenesis could be a consequence 266
of Golgi-to-ER retrograde transport inhibition. 267
Inhibition of Golgi-to-ER retrograde transport by CZM accumulates RAB1A and 268
ATG9A at the Golgi apparatus 269
To evaluate this hypothesis, we tested the effect of acute inhibition of the PSMD14 DUB 270 activity on the distribution of proteins implicated in the initial steps of autophagosome 271 formation, which traffics in early compartments of the secretory pathway. We first tested 272 RAB1A, a small GTPase with an essential role in the initiation of autophagy, facilitating 273 the recruitment of the unc-51-like kinase 1 (ULK1) complex to subdomains of the ER, a 274 crucial early step during autophagosome formation 57,58 . We found that CZM treatment 275 caused a redistribution of RAB1A to the perinuclear zone ( Fig. 7A ). Measuring these 276 images confirmed a significant increase of RAB1A in this area (Fig. 7B ), a result that was 277 accompanied by a decrease of RAB1A in the cell periphery defined as radial zone (Fig.  278 7B). Importantly, we found that RAB1B was not affected by the same condition (data not 279 shown). Moreover, we observed that RAB1A was distributed in the swollen Golgi 280 apparatus, similar to GM130, upon CZM treatment (Suppl. Fig. 5 ). With the same aim, we 281 studied the distribution of ATG9A, an essential transmembrane protein involved in 282 macroautophagy, which plays a crucial role in the early steps of autophagosome formation 283 59, 60 . ATG9A-containing vesicles are formed from the Golgi apparatus translocating to the 284 ER to form the initiation site at the ER for autophagosome formation 61 . Similar to RAB1A, 285
Supplementary Figure 4
we found that acute inhibition of PSMD14 caused a redistribution of ATG9A to the 286 perinuclear zone, together with a decrease in its distribution in the radial zone ( Fig. 7C ). 287
The quantification analysis of these images is shown in Fig. 7C . Moreover, and similar to 288 RAB1A, we observed that ATG9A is distributed to the swollen GM130-Golgi apparatus 289 area upon CZM treatment (Suppl. Fig. 6 ). These results strongly indicate that blockage of 290
Golgi-to-ER retrograde transport by acute inhibition of PSMD14 DUB activity causes the 291 retention at the Golgi apparatus of key proteins implicated in early steps of autophagosome 292 formation. The PSDM14-dependent inhibition of autophagy explains the accumulation of 293 APP at the Golgi apparatus since macroautophagy has been recently demonstrated as a 294 positive regulator of protein secretion from the Golgi apparatus 62 . Collectively, these results 295
show the strong interplay between membrane transport and autophagy through a novel 296 mechanism involving the proteasome complex through the deubiquitinating activity of 297
PSMD14. 298
Discussion 299
We report here that PSMD14 DUB activity, a subunit of the 19S RP of the proteasome, 300 functions as a novel regulator of autophagosome formation. To our knowledge, this is the 301 first report demonstrating that impairment of the proteasome can have a negative impact on 302 the initiation of autophagy. Several reports have shown that inhibition of the 20S catalytic 303 In addition, we propose that Golgi-to ER retrograde transport inhibition by PSMD14 342 dysfunction might result on the accumulation of structural and/or autophagy regulatory 343 elements. In fact, the inhibition of PSMD14 caused the accumulation of ATG9A at the 344 Golgi. ATG9A is a multispanning membrane protein essential for autophagy 59,60 . ATG9A 345 is actively transported through Golgi-to-ER retrograde transport 61 and participates as a key 346 player in the biogenesis of autophagosomes 59,79 . Moreover, along with the accumulation of 347 ATG9A at the Golgi, we found increased levels of RAB1A at the Golgi apparatus. RAB1A 348 is an essential small GTPase that participates in the recruitment of the ULK1 complex to 349 subdomains of the ER for autophagy initiation 57,58 . Interestingly, and similar to PSMD14 
Preparation of protein extracts, Electrophoresis, SDS-PAGE and Western Blot analysis 468
Cells were washed in ice-cold Phosphate Buffered Saline (PBS) and lysed at 4°C in lysis 469 buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% (vol/vol) Triton X-100) 470
supplemented with a cocktail of protease inhibitors (Sigma-Aldrich). All lysates were 471 cleared by centrifugation at 16,000 x g for 20 min at 4°C, and protein concentration was 472 determined with a protein assay dye reagent (Bio-Rad Laboratories, Hercules, CA, USA). 473
Samples with an equivalent amount of protein were boiled for 5 min with Laemmli SDS-474 PAGE sample buffer, and then analyzed by SDS-PAGE. Proteins were electroblotted onto 475 nitrocellulose membranes, blocked by incubation for 30 min in PBS containing 5% (wt/vol) 476 free-fat dry milk, and incubated sequentially with primary and secondary antibodies, both 477 diluted in blocking solution, for 1 h at room temperature, or overnight at 4°C. 478
Chemiluminescence protein detection was performed using SuperSignal West Pico 479 (Thermo Fisher Scientific). b-Actin was used as an internal loading control. 480
In vitro Proteasomal Activity Assay 481
Proteasome activity was quantitatively assessed in H4 cell extracts using the b5-selective 482 fluorogenic substrate succinyl-leucine-leucine-valine-tyrosine-4-methyl-7-courmarylamide 483 (Suc-LLVY-AMC, Calbiochem, Burlington, MA, USA) using an adapted protocol 87 . 484
Briefly, cells were left untreated or treated for 4 h with different amounts of CZM (between 485 2 and 10 µM) or with 10 µM MG132. Cells were lysed in lysis buffer (20 mM Tris-HCl, 486 pH 7.2, 1 mM EDTA, 1 mM dithiothreitol (DTT) and 0.1% (vol/vol) Nonidet P-40) 487
supplemented with a cocktail of protease inhibitors (Sigma-Aldrich). Lysates were cleared 488 by centrifugation at 16,000 x g for 20 min at 4°C, and protein concentration was 489 determined with a protein assay dye reagent (Bio-Rad Laboratories, Hercules, CA, USA). 490
Soluble extracts (20 µg) were incubated for 60 min at 37°C in proteasome assay buffer (50 491 mM Tris-HCl, pH 7.2, 1 mM DTT, 0,5 mM EDTA and 100 µM Suc-LLVY-AMC) all 492 dispensed in triplicate into a 96-well black opaque plate (Nunc, Thermo Fisher Scientific). 493 Proteasome activity was measured by monitoring the production of free AMC using a 494 Synergy HT Multi-detection Microplate Reader (BioTek Instruments, VT, USA) with 495 excitation and emission wavelengths of 360 nm and 460 nm, respectively, and the data 496 were obtained by Gen5 Version 2.09.1 data analysis software. Statistical significance was 497 determined by One-Way ANOVA, followed by Dunnett's test. Value of P <0,01(**) and P 498 <0,001(***) were regarded as statistically significant and is indicated in the figure. 499
Immunofluorescence 500
Cells grown on glass coverslips were washed with PBS and fixed in 4% (vol/vol) 501 paraformaldehyde for 30 min at room temperature. After fixation, cells were washed in 502 PBS and permeabilized with 0.2% (vol/vol) Triton X-100 in PBS for 10 min at room 503 temperature. Cells were incubated with the indicated primary antibodies diluted in 504 immunofluorescence buffer (PBS containing 10% (vol/vol) FBS and 0.1% (wt/vol) 505 Saponin) for 30 min at 37°C. Coverslips were washed in PBS and incubated with the 506 corresponding Alexa-conjugated secondary antibody diluted in immunofluorescence buffer 507 for 30 min at 37°C. For nuclei staining, cells were washed with PBS and incubated for 10 508 min at room temperature with 0.1 mg/ml DAPI. After the final wash, coverslips were 509 mounted onto glass slides with Fluoromount-G (SouthernBiotech, Birmingham, AL, USA). 510
Fluorescence Microscopy 511
Images of fixed cells were acquired by using a TCS SP8 laser-scanning confocal 512 microscope (Leica Microsystems, Wetzlar, Germany) equipped with a 63X oil immersion 513 objective (1.4 NA), 405 nm, 488 nm and 561 nm laser lines, with Photomultiplier (PMT), a 514 
3D Golgi Reconstruction and Golgi Volume and Area Measurements 541
H4 and HeLa cells stably expressing KDELR1-GFP, under the specified conditions, were 542 fixed and immunostained with anti-GM130 or anti-Giantin, respectively. The 543 immunofluorescence protocol was performed as described above to visualize the Golgi 544 structure. For Golgi volume and area measurements, Z-stack (250 nm) fluorescence images 545 were acquired by using a TCS SP8 laser-scanning confocal microscope (Leica 546 Microsystems, Wetzlar, Germany) equipped with a 63X oil immersion objective (1.4 NA) 547 running the Leica Application Suite LAS X software. Images were then processed with 548
ImageJ software version FIJI to remove the background by using threshold. The 549 thresholded images were then visualized using the "3D Viewer" plugin. The Golgi volume 550 was quantified using ImageJ software version FIJI by setting a thresholded region to select 551 only the Golgi fluorescence. Then, the Golgi structures were separated by ROI (Regions of 552 Interest) and the individual Golgi volume was measured with the plugin "Voxel Counting". 553
The Golgi volume in µm 3 was determined by the number of voxels contained in the stack of 554 images (voxel 0.2x0.2x0.25 nm). The Golgi Area was quantified using ICY software and 555 the Golgi marker GM130 was used to determine the ROI. To separate the specific signal 556 from background "k means threshold" plugin was used, using the same threshold level to 557 all images. Data analysis was performed using GraphPad Prism 6 (GraphPad Software, La 558 Jolla, CA, USA) and the results represented in graphs depicting the mean ± SEM of at least 559 20 cells. Statistical significance of the data was determined with Student's T-test. The value 560 of P <0,001(***) was regarded as statistically significant and is indicated in the respective 561
figures. 562
Densitometric Quantification and Statistical Analysis 563
The amount of immunoblot signal was estimated using Image J software version 1. 
